Publication Date
6-1-2023
DOI
10.1016/j.psycom.2023.100111
PMID
37263358
PMCID
PMC10299759
PubMedCentral® Posted Date
6-27-2023
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Obsessive-compulsive disorder, Serotonin reuptake inhibitors, Cognitive behavioral therapy, Randomized controlled trial, Children, Youth, Pediatric
Abstract
Obsessive-compulsive disorder (OCD) affects 1-2% of children and is associated with functional impairment and diminished quality of life. Several treatments are efficacious: cognitive behavioral therapy (CBT) with exposure and response prevention, serotonin reuptake inhibitor (SRI) monotherapy, and combined treatment (SRI + CBT). Expert clinician-informed practice parameters suggest that youth with mild to moderate OCD should be treated initially with CBT yet SRIs are frequently employed as the first-line intervention or in combination with psychotherapy in applied practice. Empirical data to guide SRI discontinuation in pediatric OCD are very limited. This study, Promoting OCD Wellness and Resiliency (POWER), aims to address this gap through a two phase, double-blinded, placebo-controlled, randomized controlled non-inferiority trial with the purpose of evaluating whether youth with OCD on an SRI can discontinue their medication after successful CBT augmentation and maintain wellness for a period of 24 weeks during which they receive maintenance CBT that models standard-of-care. In this paper we describe the rationale and methodological design of the POWER study.
Included in
Medical Sciences Commons, Mental and Social Health Commons, Pediatrics Commons, Psychiatry and Psychology Commons, Psychology Commons
